RxDoctor Payments Data

Garry Millien, MD

Family Medicine · West Palm Beach, FLNPI 1689628224

Payments from drug & device makers

$778in general payments, 2019–2025

Across 24 payments — averaging $32.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$232
  • UCB, Inc.$183
  • Gilead$122
  • Viatris Specialty LLC$69
  • Hologic Sales And Service, LLC$64
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$76598%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$778 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$305,581
Medicare patients
325
Services billed
2,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban312$95,878
JardianceEmpagliflozin73$51,745
DescovyEmtricitabine/Tenofov Alafenam13$29,925
XareltoRivaroxaban56$21,235
EvotazAtazanavir Sulfate/Cobicistat14$19,816
YupelriRevefenacin31$18,173
Potassium Chloride176$12,875
JanuviaSitagliptin Phosphate34$12,322
EntrestoSacubitril/Valsartan26$12,146
Pantoprazole Sodium212$11,635
Atorvastatin Calcium422$6,851
Gabapentin331$6,566
RytaryCarbidopa/Levodopa27$6,355
LinzessLinaclotide11$6,264
Levetiracetam159$6,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy$122$29,92513 claims
Mylan Specialty L.p.Yupelri$232$18,17331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →